BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia
BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia
The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in
 comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration
 pneumonia.
Inclusion Criteria:

 -  Male or female patients aged 18 years or above

 -  The primary diagnosis is community or hospital acquired primary pulmonary abscess or
 aspiration pneumonia, requiring initial parenteral treatment

 Exclusion Criteria:

 -  Known hypersensitivity to fluoroquinolones and/or ß-lactams

 -  Patients with mechanical ventilation lasting more than 48 hours prior to enrollment,
 with poststenotic pneumonia, infarction pneumonia, pulmonary tuberculosis, lung
 abscess/pneumonia with concomitant endocarditis